ArticleScientific reports2026
MST1/Drp1 axis mediates microglia pro-inflammatory activation following cerebral ischemia-reperfusion injury.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The present study investigated the role of the mammalian sterile 20-like kinase 1/dynamin-related protein 1 (MST1/Drp1) axis in regulating microglia pro-inflammatory activation during cerebral ischemia-reperfusion injury (CIRI). An in vivo model of middle cerebral artery occlusion/reperfusion (MCAO/R) in rats and an in vitro oxygen-glucose deprivation/reoxygenation (OGD/R) model in BV-2 microglial cells and primary microglia were established. Inhibitors of MST1 (XMU-MP-1) or/and Drp1 (Mdivi-1), along with genetic approaches including siMST1-mediated knockdown and plasmid-based overexpression, were utilized in the models. The expression and activation of MST1 and Drp1, mitochondrial morphology changes, microglia pro-inflammatory activation makers, pro-inflammatory cytokine release, DNA fragmentation and neurological function were evaluated. The findings indicated that reperfusion or reoxygenation led to a rise in total and phosphorylation levels of MST1 and Drp1. The reperfusion also facilitated the Drp1 translocation toward mitochondria, and resulted in increased mitochondrial morphological changes. MST1 or/and Drp1 inhibitors decreased p-MST1 and p-Drp1(Ser616) levels, attenuated mitochondrial fission, suppressed microglia pro-inflammatory activation, pro-inflammatory factors release (TNF-α, IL-6 and IL-1β). Overall, these effects ultimately mitigated cerebral injury as evidenced by reduced DNA fragmentation, decreased cerebral infarct volumes, and improved neurological function. Combined inhibitors further exerted ameliorative effects on the above-mentioned parameters. In the in vitro experiments, siMST1 knockdown attenuated p-Drp1(Ser616) expression and suppressed microglia pro-inflammatory activation under OGD/R conditions. These protective effects were reversed by Drp1 overexpression. These findings indicate that p-MST1 drives microglia pro-inflammatory activation via promoting the p-Drp1(Ser616)-mediated excessive mitochondrial fission during CIRI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.